We’re improving your experience!
Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Linifanib |
| Synonyms | |
| Therapy Description |
Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Linifanib | ABT-869|AL-39324 | CSF1R Inhibitor 28 FLT3 Inhibitor 69 KIT Inhibitor 57 PDGFR-beta Inhibitor 14 VEGFR Inhibitor (Pan) 36 | Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 D835K FLT3 D835L | hematologic cancer | no benefit | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) did not inhibit viability of transformed cells expressing FLT3 D835L and D835K in culture (PMID: 28077790). | 28077790 |
| FLT3 I836S | hematologic cancer | no benefit | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) did not inhibit viability of transformed cells expressing FLT3 I836S in culture (PMID: 28077790). | 28077790 |
| FLT3 I836D FLT3 I836L | hematologic cancer | no benefit | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) did not inhibit viability of transformed cells expressing FLT3 I836D and I836L in culture (PMID: 28077790). | 28077790 |
| FLT3 Q575del | hematologic cancer | sensitive | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) decreased proliferation in transformed cells expressing FLT3 Q575del in culture (PMID: 33914060). | 33914060 |
| FLT3 I836T | hematologic cancer | sensitive | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) inhibited viability in transformed cells expressing FLT3 I836T in culture (PMID: 28077790). | 28077790 |
| FLT3 D835G | hematologic cancer | sensitive | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) inhibited viability in transformed cells expressing FLT3 D835G in culture (PMID: 28077790). | 28077790 |
| FLT3 D835N | hematologic cancer | sensitive | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) inhibited viability in transformed cells expressing FLT3 D835N in culture (PMID: 28077790). | 28077790 |
| FLT3 D835A | hematologic cancer | no benefit | Linifanib | Preclinical - Cell culture | Actionable | In a preclinical study, Linifanib (ABT-869) did not inhibit viability of transformed cells expressing FLT3 D835A in culture (PMID: 28077790). | 28077790 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|
CKB BOOST